Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

Raja, F A, Griffin, C L, Qian, W, Hirte, H, Parmar, M K, Swart, Ann Marie and Ledermann, J A (2011) Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. British Journal of Cancer, 105 (7). pp. 884-889. ISSN 0007-0920

Full text not available from this repository. (Request a copy)

Abstract

Background: Cediranib is a potent oral vascular endothelial growth factor (VEGF) signalling inhibitor with activity against all three VEGF receptors. The International Collaboration for Ovarian Neoplasia 6 (ICON6) trial was initiated based on evidence of single-agent activity in ovarian cancer with acceptable toxicity. Methods: The ICON6 trial is a 3-arm, 3-stage, double-blind, placebo-controlled randomised trial in first relapse of platinum-sensitive ovarian cancer. Patients are randomised (2?:?3?:?3) to receive six cycles of carboplatin (AUC5/6) plus paclitaxel (175?mg?m-2) with either placebo (reference), cediranib 20?mg per day, followed by placebo (concurrent), or cediranib 20?mg per day, followed by cediranib (concurrent plus maintenance). Cediranib or placebo was continued for 18 months or until disease progression. The primary outcome measure for stage I was safety, and the blinded results are presented here. Results: Sixty patients were included in the stage I analysis. A total of 53 patients had received three cycles of chemotherapy and 42 patients had completed six cycles. In all, 19 out of 60 patients discontinued cediranib or placebo during chemotherapy because of adverse events/intercurrent illness (n=9); disease progression (n=1); death (n=3); patient decision (n=1); administrative reasons (n=1); and multiple reasons (n=4). Grade 3 and 4 toxicity was experienced by 30 (50%) and 3 (5%) patients, respectively. No gastrointestinal perforations were observed. Conclusion: The addition of cediranib to platinum-based chemotherapy is sufficiently well tolerated to expand the ICON6 trial and progress to stage II.

Item Type: Article
Uncontrolled Keywords: icon6,relapsed ovarian cancer,cediranib
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 24 Sep 2013 00:54
Last Modified: 01 May 2020 23:44
URI: https://ueaeprints.uea.ac.uk/id/eprint/43384
DOI: 10.1038/bjc.2011.334

Actions (login required)

View Item View Item